DRUG
GLP-1 Receptor Agonists
like semaglutide、tirzepatide、liraglutide，etc.
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation
Status
Completed
Phase
Not applicable
Enrollment
213,891
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Background: Seven large real-world cohort studies (N \> 4 million) have consistently reported that glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a 19-54% lower incidence of Alzheimer's disease (AD). However, in November 2025, the phase 3 EVOKE and EVOKE+ trials of oral semaglutide in 3,808 patients with biomarker-confirmed early-stage AD failed to slow clinical progression. This paradox between real-world evidence (RWE) and randomised evidence has not been systematically examined. Moreover, prior RWE studies were conducted predominantly in North American and European populations, leaving a critical generalisability gap for East Asian populations, who face the world's largest AD burden. Objective: To resolve the RWE-RCT paradox by testing whether the GLP-1RA effect on AD differs between cognitively unimpaired adults (primary prevention paradigm) and patients with established cognitive impairment (treatment paradigm), and to assess whether the protective effect is consistent across European, African, and East Asian ancestries. Study Design: This is a multi-centre, retrospective, observational cohort study using a target trial emulation framework. The investigator analysed patient-level electronic health records (EHR) from five cohorts across four continents: Optum® Clinformatics® (USA), Mass General Brigham Biobank (USA), CPRD Aurum (UK), the Swedish National Diabetes Register (Sweden), and the Hong Kong Hospital Authority Clinical Data Analysis and Reporting System (HKHA CDARS), which covers approximately the entire Hong Kong population. Study Population: A total of 2,138,917 adults aged ≥ 40 years with type 2 diabetes or obesity, with ≥ 2 years of continuous enrolment and no prior neurodegenerative disease diagnosis. GLP-1RA initiators (n = 612,418) were compared with DPP-4 inhibitor initiators (n = 1,526,499) using propensity-score overlap weighting, Fine-Gray competing-risk adjustment, negative-control outcomes, and instrumental-variable analysis to address confounding and surveillance bias.
Interventions
Treatment arms and agents.
DRUG
DPP-4 Inhibitors
Sitagliptin,Saxagliptin,Vildagliptin,Linagliptin,Alogliptin etc.
Timeline
From registration to results.
First posted
Jul 1, 2026
Study start
Jan 1, 2007
Primary completion
Dec 31, 2024
Study completion
Jun 24, 2026
Results posted
Not reported
Registry updated
Jul 1, 2026
Outcomes
What the study measures.
Primary outcomes
Incidence of Alzheimer's Disease
Time frame · Up to 10 years (from index date of medication initiation to date of first AD diagnosis, death, or end of follow-up, whichever occurs first).
Measurement Tool: International Classification of Diseases, Tenth Revision (ICD-10) diagnostic code G30 (Alzheimer's disease), extracted from linked electronic health records (EHR) and hospitalization databases across all participating cohorts. Diagnostic validity was confirmed via chart review against biomarker-confirmed AD (amyloid PET, CSF Aβ42, or plasma p-tau217), with a positive predictive value (PPV) ranging from 68.9% to 71.3% in validation samples. Unit of Measure: Time to first incident diagnosis, expressed as Hazard Ratio (HR) with 95% confidence intervals, comparing GLP-1 receptor agonist initiators versus DPP-4 inhibitor initiators. Incidence rates are also reported as number of events per 1,000 person-years. Scale Information: Not applicable (this is a time-to-event diagnostic outcome, not a rating scale).
Secondary outcomes
Incidence of All-Cause Dementia.
Time frame · Up to 10 years
Measurement Tool: ICD-10 codes for any dementia diagnosis, including Alzheimer's disease (G30), vascular dementia (F01), and unspecified dementia (F03), extracted from EHR and hospitalization records. Unit of Measure: Time to first diagnosis, expressed as Hazard Ratio (HR) with 95% CI. Scale Information: Not applicable (diagnostic outcome).
Rate of Progression from Mild Cognitive Impairment (MCI) to Alzheimer's Disease
Time frame · Up to 10 years
Measurement Name: Rate of Progression from MCI to AD. Measurement Tool: ICD-10 code G31.84 (Mild cognitive impairment) at baseline, followed by subsequent ICD-10 code G30 (Alzheimer's disease) during follow-up, extracted from EHR. Unit of Measure: Time to progression, expressed as Hazard Ratio (HR) with 95% CI, specifically analyzed within the EVOKE-eligible patient subgroup (those with baseline cognitive impairment). Scale Information: Not applicable (diagnostic progression outcome).
Rate of All-Cause Mortality.
Time frame · Up to 10 years.
Measurement Tool: Death records linked from national or regional death registries (e.g., Hong Kong Death Registry, Swedish National Death Registry, UK Office for National Statistics). Unit of Measure: Time to death, expressed as Hazard Ratio (HR) with 95% CI, analyzed using Fine-Gray subdistribution hazard models to account for competing risks. Scale Information: Not applicable (mortality outcome).
Eligibility
Who can take part.
- Minimum age
- 40 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * • Age ≥ 40 years * Diagnosis of type 2 diabetes (ICD-10 E11) or obesity (E66) * ≥ 2 years of continuous enrolment in the cohort * Baseline HbA1c \< 10.5% * No prior diagnosis of any neurodegenerative disease * No prior use of any GLP-1RA or DPP-4i Exclusion Criteria: * • Prior diagnosis of Alzheimer's disease or other neurodegenerative diseases * Prior use of GLP-1 receptor agonists or DPP-4 inhibitors * Age \< 40 years * Baseline HbA1c ≥ 10.5% * Less than 2 years of continuous enrolment
Study locations
1 registered sites.
China. Showing up to 24 locations stored in the fast local snapshot.
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Tirzepatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Obesity & Overweight
Not applicable
Recruiting
24
2026-07
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
Shahid Beheshti University of Medical Sciences · Heart Failure and Reduced Ejection Fraction · Obesity & Overweight
Phase 3
Not yet recruiting
60
2026-07
Tirzepatide Impact Assessment Study
Texas Tech University · Obesity & Overweight · Cardiometabolic Health Indicators
Not applicable
Recruiting
27
2026-07
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Alaa Sada · Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status
Phase 2
Recruiting
34
2026-07
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
yifang zhu · Acute Ischemic Stroke (AIS)
Phase 2 / Phase 3
Not yet recruiting
430
2026-07
Tirzepatide for Treatment of CCCA
Johns Hopkins University · Central Centrifugal Cicatricial Alopecia (CCCA)
Phase 2
Not yet recruiting
20
2026-07
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Duke University · Idiopathic Intracranial Hypertension (IIH)
Phase 4
Not yet recruiting
60
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.